STOCK TITAN

InMed director Julianne Bruno holds 33,442 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
3

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. director Julianne Bruno reported a direct holding of 33,442 common shares following the November 6, 2026 merger. She received the shares in exchange for Pre-Merger Mentari common shares she held before the merger. Of the reported shares, 23,689 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to her continued service.

Insider Bruno Julianne
Role Director
Type Security Shares Price Value
Holding Common Stock F1, F2 -- -- --
Holdings: Common Stock — 33,442 shares (Direct)
Footnotes (2)
  1. F1. Effective as of November 6, 2026 (the "Effective Time"), (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
  2. F2. Represents shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Mentari's restricted common stock held at the Effective Time was exchanged for 0.20065 restricted shares of the Issuer's common stock. Of these shares of common stock, 23,689 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Direct common shares held after merger 33,442 shares Julianne Bruno’s reported holdings following the November 6, 2026 merger
Restricted shares subject to forfeiture 23,689 shares Vest in equal monthly installments through August 13, 2029, subject to continued service
Restricted-share exchange ratio 0.20065 restricted shares per share Each Pre-Merger Mentari restricted common share held at the effective time was exchanged for this number of issuer common shares
forfeiture restrictions technical
"remain subject to forfeiture restrictions"
vesting technical
"vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Effective Time technical
"Effective as of November 6, 2026 (the "Effective Time")"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did INM director Julianne Bruno report holding?

Julianne Bruno reported a direct holding of 33,442 shares of common stock following the November 6, 2026 merger. She received the shares in exchange for Pre-Merger Mentari common shares she held before the merger.

What exchange ratio applied to restricted stock in the INM merger?

Each share of Pre-Merger Mentari restricted common stock held at the effective time was exchanged for 0.20065 restricted shares of the issuer’s common stock. The 23,689 shares that remain subject to forfeiture vest in equal monthly installments through August 13, 2029, subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Bruno Julianne

(Last)(First)(Middle)
C/O MENTARI THERAPEUTICS, INC.
221 CRESCENT ST., BUILDING 23, SUITE 105

(Street)
WALTHAM MASSACHUSETTS 02453

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
11/06/2026
3. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ MTRI ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock33,442(1)(2)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Effective as of November 6, 2026 (the "Effective Time"), (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
2. Represents shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Mentari's restricted common stock held at the Effective Time was exchanged for 0.20065 restricted shares of the Issuer's common stock. Of these shares of common stock, 23,689 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Jerad G. Seurer, as attorney-in-fact for Julianne Bruno11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Keep reading